Figure 5
Antitumor activity of CAR.GD2 NKT cells in a metastatic NB model in hu-NSG mice. Three months after human cord blood stem cell transfer, each mouse received IV injection of 106 CHLA-255(ffluc+) NB cells followed by (day 7) injection of 107 CAR.GD2 NKT cells with the indicated constructs. For group “Repeat G28BBz,” additional injections were given on days 14 and 21. (A) Tumor growth was monitored using weekly bioluminescent imaging. Shown are 3 representative of 7 mice per group from 1 of 3 independent experiments. (B) Shown is a representative survival plot from 1 of 3 experiments. Data were analyzed by the Kaplan-Meier method. The differences in survival were then compared using the Gehan-Wilcoxon test.
